Kaposi's Sarcoma - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• Although Kaposi sarcoma cannot be cured, several effective treatment options exist. When Kaposi sarcoma is associated with immunodeficiency (AIDS-associated Kaposi sarcoma) or immunosuppression (transplant-related Kaposi sarcoma), reversing the immunocompromised state is the first-line approach.
• For self-limited cutaneous disease, localized treatment of the lesions is the recommended approach. Cryosurgery or laser treatment can be considered for superficial lesions, but these approaches carry a risk of hypopigmentation.
• In the United States, most cases of Kaposi sarcoma are related to HIV. All forms of Kaposi Sarcoma are more common in men than in women.
• The HIV epidemic has significantly contributed to the rise in kaposi sarcoma cases.
• As per secondary search, Kaposi sarcoma affects 6 in 1 million people with HIV/AIDs and 1 in 200 people taking immunosuppressants after stem cell (bone marrow) transplant or organ transplant surgery.
• The treatment of Kaposi’s sarcoma consists of antiretroviral therapies, radiation therapy, chemotherapy, drugs such as POMALYST (pomalidomide), and several biological therapies to boost the immune system.
• The emerging pipeline for Kaposi sarcoma remains limited, with only one therapy - LYMPHOSEEK, currently in the preclinical phase which is being developed by Navidea Biopharmaceuticals.

The “Kaposi Sarcoma - Market Insight, Epidemiology and Market Forecast - 2034” report delivers an in-depth analysis of Kaposi sarcoma epidemiology, market, and clinical development in Kaposi sarcoma. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Kaposi sarcoma market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Kaposi sarcoma market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted Kaposi sarcoma market size from 2020 to 2034 in 7MM. The report also covers current Kaposi sarcoma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Kaposi Sarcoma Understanding and Treatment Algorithm

Kaposi Sarcoma Overview

Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma-associated herpes virus (KSHV), which is also known as herpes virus 8 (HHV8). KSHV is in the same family as Epstein-Barr virus (EBV), the virus that causes infectious mononucleosis and is linked to several types of cancer. There are four main forms of Kaposi sarcoma: Epidemic or AIDS-associated, Classic, Endemic, and Immunosuppressive.

Kaposi Sarcoma Diagnosis

Kaposi's sarcoma is usually diagnosed through clinical examination and tissue biopsy. The doctors might also use different diagnostic methods, which are: Fecal occult blood tests, Endoscopy/colonoscopy, bronchoscopy, and imaging tests, to confirm the diagnosis of the same.

Kaposi Sarcoma Treatment

The treatment of Kaposi sarcoma depends on the clinical category, the extent of lesion involvement, and the pre‐existing medical conditions of the patient. Therapeutic options for the management of Kaposi sarcoma range from clinical observation for indolent solitary lesions, initiation or optimization of antiretroviral therapy for AIDS‐related Kaposi sarcoma, to systemic chemotherapeutic agents for disseminated disease. For patients with cutaneous Kaposi sarcoma, recent clinical guidelines have recommended radiotherapy, surgical excision, cryosurgery, laser therapy, and intralesional agents as treatment modalities. Although these treatments are effective in most cases, they may not be feasible for all patients; their use is dependent on patient comorbidities, as well as the anatomical locations and extent of Kaposi sarcoma lesions. Topical treatment may be more appropriate for some cases of cutaneous Kaposi sarcoma, as it potentially allows higher drug levels at the tumor site, lower degrees of pain and scarring, and better safety profiles. Currently, POMALYST (pomalidomide) is approved for the treatment of Kaposi sarcoma.

Kaposi Sarcoma Epidemiology

The Kaposi sarcoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total prevalent cases of Kaposi sarcoma, total diagnosed prevalent cases of Kaposi sarcoma, gender-specific cases of Kaposi sarcoma, age-specific cases of Kaposi sarcoma, cases of Kaposi sarcoma sub-type, and total treated cases of Kaposi sarcoma in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• Among the 7MM, the United States has captured the highest market share of Kaposi sarcoma in 2024.
• As per the secondary search, the overall 5-year relative survival rate for Kaposi sarcoma is approximately 75%.
• Kaposi sarcoma is more common in men and patients with suppressed immune systems.
• Kaposi sarcoma is more prevalent in middle-aged or elderly men, aged 70 years or older, and only 4-8% of cases develop in younger individuals.

Kaposi Sarcoma Drug Chapters

The drug chapter segment of the Kaposi sarcoma report encloses a detailed analysis of Kaposi sarcoma-marketed drugs and emerging pipeline drugs. It also deep dives into Kaposi sarcoma’s pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Drugs

POMALYST (pomalidomide): Bristol Myers Squibb

POMALYST is a thalidomide analog indicated for the treatment of adult patients in combination with dexamethasone, for patients with multiple myeloma and with AIDS-related Kaposi sarcoma after failure of Highly Active Antiretroviral Therapy (HAART) or in patients with Kaposi sarcoma who are HIV-negative. This indication is approved under accelerated approval based on the overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trials.

In March 2020, POMALYST was approved by the US Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to HAART, or in patients with Kaposi sarcoma who are HIV-negative.

Drug Class Insights

Currently, POMALYST is the only marketed therapy used for the treatment of Kaposi sarcoma. Pomalidomide, derived from thalidomide, functions as an immunomodulatory agent with anticancer properties. In laboratory cell tests, pomalidomide effectively suppressed the growth and triggered cell death in hematopoietic tumor cells. It also demonstrated efficacy against multiple myeloma cell lines resistant to lenalidomide, particularly when combined with dexamethasone, enhancing tumor cell apoptosis. Furthermore, pomalidomide boosted immune responses mediated by T cells and natural killer cells while reducing the production of inflammatory cytokines by monocytes.

Kaposi Sarcoma Market Outlook

Treatment options include local therapies like surgery, radiation, and cryotherapy for localized lesions, and systemic therapies like chemotherapy and targeted therapy for more advanced or widespread disease. Antiretroviral therapy is crucial for AIDS-related kaposi sarcoma, as it can significantly impact disease progression.

The treatment and management of kaposi sarcoma present several challenges, particularly in resource-limited settings. One of the primary challenges is the early detection and diagnosis of kaposi sarcoma, especially in regions where healthcare infrastructure is underdeveloped. Many cases of kaposi sarcoma go undiagnosed or are diagnosed at a late stage, when the disease is more difficult to treat.

The dynamics of the Kaposi's sarcoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and the expected launch of emerging therapies. More research is needed to develop a better understanding of Kaposi sarcoma phenomenology across the developmental spectrum, the biological mechanisms underlying the disorder, and how best to make use of the treatments already developed that have shown efficacy for Kaposi sarcoma. Many research organizations, such as Rabin Medical Center, AIDS Malignancy Consortium, National Cancer Institute (NCI), University of Arkansas, and University of California, Los Angeles, among others, are actively researching Kaposi's sarcoma, and several trials are being conducted by them.

Kaposi Sarcoma drug uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Kaposi Sarcoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in the marketed and emerging stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Kaposi sarcoma therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as UT Health San Antonio MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Kaposi sarcoma market trends.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated.

Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of Kaposi sarcoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Kaposi sarcoma market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Kaposi sarcoma market.

Kaposi Sarcoma Report Insights

• Patient Population
• Therapeutic Approaches
• Kaposi Sarcoma Pipeline Analysis
• Kaposi Sarcoma Market Size and Trends
• Existing and Future Market Opportunity

Kaposi Sarcoma Report Key Strengths

• Ten-Year Forecast
• 7MM Coverage
• Kaposi Sarcoma Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Kaposi Sarcoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

FAQs

• What was the Kaposi sarcoma total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors for this growth?
• At what CAGR, the Kaposi sarcoma market is expected to grow at the 7MM level during the study period (2020-2034)?
• How is Japan's Kaposi sarcoma competitive landscape evolving?
• How will upcoming emerging therapies are going to impact POMALYST’s market share?
• What are the disease risks, burdens, and unmet needs of Kaposi sarcoma?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Kaposi sarcoma?
• What is the historical and forecasted Kaposi sarcoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What factors are affecting the increase in the diagnosis of symptomatic cases?
• What are the current options for the treatment of Kaposi sarcoma? What are the current treatment guidelines for the treatment of Kaposi sarcoma in the US and Europe?
• How many companies are developing therapies for the treatment of Kaposi sarcoma?
• What key designations have been granted for the emerging therapies for Kaposi sarcoma?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Kaposi sarcoma market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand KOLs’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.